7 epls conference, prague manuela mueller-gerndt · pdf file7th epls conference, prague...
TRANSCRIPT
© 2014 HCL – Proprietary & Confidential
7th EPLS Conference, Prague
Manuela Mueller-Gerndt
23rd September 2014
New business models – interface with Pharma
201
3© 2014 HCL – Proprietary & Confidential
HCL: Quick Facts
3
B I L L I O N C O U N T R I E S P E O P L E
HCL Technologies
Global Market Focus
Enterprise & Custom Applications,
Infrastructure Services ,Product
Engineering & R&D and BPO Services
HCL Infosystems
Indian Market Focus
Hardware, System Integration,
Networking Solutions, Managed ISP
Services, Homeland Security & ICT
Distribution
$6.2 31 90000
What HCL Stands for
HCL EnterpriseHCL
Avitas
426
5© 2014 HCL – Proprietary & Confidential
Life Sciences Service Offerings
Information
Management &
Professional
Services
BPO & Infrastructure
Application Support
& Enhancement
Application Dev.
& Management
Portals &
Content Management
Compliance
& Validation
Target
Identification &
Validation
Hit Identification
Lead Generation &
Optimization
Predictive
Computational
Chemistry Tools
Lab Automation
Procurement
Factory
Solutions
Enterprise
Solutions
Automation
Solutions
Consulting
MES
LEAN
Marketing
Management
Sales Force
Management
Sales Support
Solutions
Consulting
CRM
Validation
GAMP5
ASTM
Submission
Consultancy
Audit
Compliance:
ICH
USFDA and
related
regulations
Preclinical
Protocol
Development
Clinical Trial
Management
Clinical Data
Management
Data Analysis
Submissions
Lab
Automation
ERP
Middleware
Content
Management
Consulting
Service
Management
DW/BI
Siebel eClinical
Oracle Clinical
Remote Data
Capture
LIMS, ELN
CDS, SDMS
Phase Forward
ICH, GCP,
SOPs
Oracle iLife
Sciences
MSFT
Dynamics
Veeva
SFDC
Oracle AERS
Argus
Siebel AECM
eMDR
Document
Management
Oracle Agile
OPSM
OTM
Demantra
LIMS, ELN
CDS, SDMS
SAP
Fusion, BEA
Aqua Logic
Siebel
JDE
Oracle EBS
PeopleSoft
CRM On
Demand
SAP
Accelrys
LIMS
ELN
Drug DiscoveryManufacturing
& SCM IT
Sales &
MarketingRegulatory
Drug
DevelopmentEnterprise IT
Clinical Transformation Real World Evidence Commercial Transformation• Discovery Drug Design Optimization
• Comparative Effectiveness Research (CER)
• Clinical Trial Optimization
• Value Based Pricing (VBP)
• Optimal Treatment Indicators
• Evidence based Medicine (EBM)/Evidence
based Practice (EBP)
• Sales Operations Outsourcing
• Sales Reporting and Analytics:
• Enhanced Direct Sales Support (Call Centre):
• Campaign and Brand Management
• Compliance Services (Statutory Compliance)
• Contract Sales Organization Optimization
• Integrated Clinical Platform SI and ADM
Services across EDC, CTMS, LSH, Safety,
Risk Management, CDW for Oracle
HSGBU Products and Custom Apps
• Unified Clinical Platform on a Hosted
Model – Integrated EDC, CTMS, LSH ,
Safety and CDA Environment
• Functional KPO Services
Fu
lly L
oa
de
d
Se
rvic
e L
ine
s
HCL’s Investments
2.400+ consultants250+ consultants 500+ consultants 80 consultants 190 consultants 260 consultants 800+ consultants
6© 2014 HCL – Proprietary & Confidential
Representative customers across all functional areas
Drug Discovery
Drug Development
Manufacturing & SCM IT
Distribution/ Enterprise IT
Sales & Marketing
7© 2014 HCL – Proprietary & Confidential7
“Creatively converge Technology, Data and Services around the
patient to fundamentally transform Patient Insights, Patient
Outcomes, Patient Experience and HC Reach Globally. “
Our Vision is based on four convergent drivers continuing to create a major inflexion point
on Patient behaviours and expectations relating to Healthcare globally. Over the foreseeable
future they will have an increasing impact in transforming the way patients perceive, receive
and believe in Healthcare; to move Patients from a victim mindset of ‘Heal Me’ to a more
positive, proactive mindset of ‘Help me heal myself’.
HCL Healthcare : Vision Statement
8
The opportunity: healthcare inefficiency
Source: IBM Institute for Business Value
9© 2014 HCL – Proprietary & Confidential
Industry challenges
and opportunities
Market Forces Driving Life Science Transformation
Quality and efficiency
of Life Sciences products challenge
the current drug safety models
New market entrants
and treatment
approaches challenge
existing models
Complex and
inefficient Life
Sciences R&D
contribute to
weak pipeline
Tougher and tighter
regulations mandate higher
standards of compliance
Globalization
and the new economic
environment tax
development resources
Generic versions of
blockbuster drugs create
pricing pressures
Empowered patients call
for more effective therapies
Source: IBM Institute for Business Value
10
Business Structure Modernization
Information Readiness and Analytics
Evolution of
Care DeliveryEcosystem
Convergence
Movement to
Consumerism
We see transformation in the Healthcare and Life Sciences industries
around three major business trends, supported by two fundamental
capabilities
11 9/29/2014
New care delivery models are evolving to be preventative and more
focused on wellness and outcomes
Today’s Care Tomorrow’s Care
Our patients are those who are registered in our medical home or invisible in an ACO
Care is determined by today’s problem and time available today
Care is determined by a proactive plan to meet health needs, with or without visits
Care varies by scheduled time and memory or skill of the doctor
Care is standardized according to evidence-based guidelines
Patients are responsible for coordinating their own care
A prepared team of professionals coordinates all patients’ care
I know I deliver high quality care because I’m well trained
We measure our quality and make rapid changes to improve it
It’s up to the patient to tell us what happened to them
We track tests and consultations, and follow-up after emergency department and hospital
Clinic operations center on meeting the doctor’s needs
An interdisciplinary team works at the top of our licenses to serve patients
My patients are those who make appointments to see me
Source: Adapted with permission by IBM from Daniel F. Duffy, M.D.
12
Piloting a care coordination solution enabled with predictive analytics to prevent crisis in progressive chronic disease patients
Developing advanced analytics predictive models to improve physician targeting and segmentation defining next best action
Developed remote heath monitoring light weight care coordination solution
Piloting a hospital transition in care solution offering targeting reducing 30 day readmissions for CHF, AMI, PNA
Traditional product provider
Product wrap around service
Therapeutic area solution provider
Health Solutions Provider
Traditional model of increased market share, quicker uptake, and improved brand loyalty
Traditional model of increased market share based on improved market place perception, value add services, and differentiation
B2B business model targeting government entities as the customers; revenue through an initial fee and then a per patient charge
B2B model, targeting hospitals as the primary customers; charging an initial fee, a per patient charge, then evolving to a B2B2C model
Advanced commercial analytics
Front end and patient engagement services
More sophisticated front end, care coordination services, data integration, and advanced Healthcare analytics
More sophisticated front end, sophisticated care coordination services, and data integration
Scope
System
Business Model
Commercial Effectiveness Business Transformation
There is a desire to move to large-scale, patient-centric services that
monitor outcomes
Value to Healthcare EcosystemSupplier ofProducts / Devices
SolutionsProvider
Source: IBM Institute for Business Value
13
Healthcare model disruption and scalability
Source: Ernst & Young, The New Healthcare Ecosystem
14
Data is called the new „oil“
Source: Gartner, 2013
15
Big Data is more than just volume
Volume
Terabytes to
exabytes of
existing data
to process
Velocity
Streaming data,
milliseconds to
seconds to
respond
Variety
Structured,
unstructured,
text and
multimedia
Veracity
Uncertainty from
inconsistency,
ambiguities, etc.
Source: IBM Institute for Business Value
16
vital-signs are captured by
bedside monitoring devices
Volume Velocity Variety
1,000/sec
Real-time analysis of
device data, images &
alerts will change the role
of monitoring devices in
healthcare outcomes and
patient wellbeing.
Research data is spread
across huge databases of
patents, compounds, journals,
biomarkers, structure activity
relationships, genomics, and
medical records
Advancing population health
and personalized medicine
with variety of data inputs from
medical records, notes and
dictation; public health reports;
social media and web content
unstructured data in EMRs,
devices, publications, drug
structures…
80%
unique molecules in the
ChemSpider chemical
database, from 400+ sources
26million
What does Big Data mean for Life Sciences?
Source: IBM Institute for Business Value
17© 2014 HCL – Proprietary & Confidential
Real-time monitoring platform with a patient centricity approach,
covering a multi-device approach – one of many examples
Design Interventions
Hea
lth
sta
te
mo
nit
ori
ng
Doctor
Manufacturer
Patient
Monitoring and data transmission
Data capture and analysis
Data Aggregation
AnalyticsData
CollectionInterventions
Health informationand actions
Family
Smart Packaging
Home Monitoring
Pill Dispensers
Smartphone Apps
Payor
Up
dat
e m
edic
al
reco
rds
Outcomes Monitoring Portal
Source: IBM HCLS
18© 2014 HCL – Proprietary & Confidential
Cognitive computing is a rapid evolving landscape and
combines transformational technologies
Understands
natural language
and human
communication
Adapts and learns
from user
selections and
responses
Generates and
evaluates
evidence-based
hypothesis
In 2020, approx. 80% of the technology on the
market will have cognitive services:
discovery, probabilistic, big data,
natural language.
1
2
3
Source: IBM WATSON
19
Oncology Advisor created by IBM for Wellpoint and Cancer
Centers
Source: IBM WATSON
20© 2014 HCL – Proprietary & Confidential
Implantable Pain Management System
500+ patients are
implanted with the
device in Europe.
Recently
approved by FDA
Product: Implantable device, delivers drug to spinal
chord for management of pain from muscle
contractions. The drug can be refilled from outside
and the device can be configured from outside
wirelessly for dosage management.
HCL responsibilities: Complete development of
HW and SW, prototyping and verification. Offered
support for risk management (FMEA, SHA) and
regulatory submission.
21© 2014 HCL – Proprietary & Confidential
Selected Nerve Stimulator
Nominated for
MDEA 2012
Awards
Product: Delivers electrical pulses
transcutaneously to the nerves for
treatment of over active bladder (Urinary
incontinence) for Women.
HCL responsibilities: Complete
development of HW and SW, prototyping
and verification. Offered support for risk
management (FMEA, SHA) and regulatory
submission.
22© 2014 HCL – Proprietary & Confidential
Disease Management Ecosystem
Product: iPad based SW application that can collate information from service
providers, suppliers and care givers. Can talk to set of smart devices through
blue tooth for data management and alerts
23© 2014 HCL – Proprietary & Confidential
To enable patient-centric services at scale, the
underlying technology needs to be developed in detail
CommercialModel
DeliveryModel Workflow
ProcessesReportingMetricsGovernance
Flexible, scalable architectureCloud-based or hybrid model
Robust failsafe operationsSecurity and data integrity
Virtual Counselor:Education CenterLifestyle Consults
Community Services
Real-Time Monitoring System:Health metrics monitoringData tracking and storage
Analytics & visualization
Additional Heart Health Services
Capture, aggregate & distributeAnalyse and present
User groups and rolesPersonal Profile management
Business Processes
SW Architecture
IT Infrastructure
Data ManagementApplication IntegrationPortal for multiple rolesAlerts/ CommunicationComplianceCare Protocol DeliveryRemote device monitoringClinical and operational analytics
Physicians
Patients Payors
Partners
Hub
Services
Heart Health Ecosystem
Source: IBM
24
Automotive Industry is investing in healthcare
Consuming Health on the Road
„Healthy car“
Collection of health data, vital
parameter etc.
Massage within the car
Special, „customized“ chairs
In USA: Health Teaching during
rush hours (drug education,
disease education)
Collaboration with Pharma and
IT
http://www.manager-magazin.de/lifestyle/auto/0,2828,403537-2,00.html
25
Health in the car
26
Genentech and PatientsLikeMe close a large groundbreaking 5 year
research agreement (use patient‘s real experience with diseases and
drugs for better research)
Elli Lilly & Co is rolling out a web-based service to help people learn
about particular drugs (guiding patients before diagnosis)
Bayer works with Microlife (med. dev. manufacturer) and distributes a
screening device with automated diagnosis software to physicians in
Switzerland (blood pressure and pulse, pre-diagnosis through evaluation
of measurements)
Pfizer Integrated Health: project aimed at stepping beyond the pill and
bringing together science, drugs and technology to improve patients
outcomes (help physicians making an accurate diagnosis of lower back
pain -> closed down after 2 years.)
Further examples
27
Google: Calico focuses on the challenge of aging and
associated diseases
28